Evista has not been shown to reduce the risk of noninvasive breast cancer.
Do not use Evista for a online contest 2017 india condition for which it was not prescribed.Women-years this was primarily due to an 80 reduction in the incidence of ER-positive invasive breast cancer in the Evista group compared with placebo.Generic Name: raloxifene hydrochloride, dosage Form: tablet, medically reviewed on Jun 1, 2018, show On This Page.Antacids Concomitant administration of calcium carbonate or aluminum and magnesium hydroxide-containing antacids does not affect the systemic exposure of raloxifene see Drug Interactions (.5 ).Before starting Evista, tell your doctor if you have had blood clots in your legs, lungs, or eyes, a stroke, mini-stroke (transient ischemic attack or have an irregular heartbeat.Who should not take Evista?Apparent clearance of raloxifene was reduced 56 and the half-life of raloxifene was not altered in patients with mild hepatic impairment.Apparent oral clearance.1 L/kghr.Other Concomitant Medications Evista can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin see Clinical Pharmacology (.3 ).Common adverse reactions considered to be drug-related were hot flashes and leg cramps.
The biological actions of raloxifene are largely mediated through binding to estrogen receptors.
Evista has not been adequately studied in men and its use is not recommended.There are no data available regarding the effect of Evista on invasive breast cancer incidence in women with inherited mutations (brca1, brca2) to be able to make specific recommendations on the effectiveness of Evista.Reduction in Risk of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis more Trial The effect of Evista on the incidence of breast cancer was assessed as a secondary safety endpoint in a randomized, placebo-controlled, double-blind, multinational osteoporosis treatment trial in postmenopausal women see Clinical.Raloxifene should be used with caution in patients with moderate or severe renal impairment see Warnings and Precautions (.8 ) and Use in Specific Populations (.6 ).(See What should I avoid if I am taking Evista?The results from a noninferiority analysis are consistent with Evista potentially losing up to 35 of the tamoxifen effect on reduction of invasive breast cancer.In addition, women taking Evista should be advised to move about periodically during prolonged travel.You and your doctor should talk about whether the possible benefit of Evista in lowering your chance of getting invasive breast cancer is greater than its possible risks.There was no reduction in the incidence of ER-negative breast cancer.An increased risk of death due to stroke after treatment with Evista was observed: 59 (1.2) Evista-treated women died due to a stroke compared to 39 (0.8) placebo-treated women (2.2 versus.